recurrent cervical cancer

Overview

Recurrent cervical cancer refers to cervical cancer that returns after initial treatment, typically after a period of apparent remission. It may recur locally in the pelvis, regionally in lymph nodes, or at distant metastatic sites. Clinically, recurrent disease is often grouped with persistent or metastatic cervical cancer because these settings share similar therapeutic challenges, including treatment resistance, limited curative options, and the need for individualized systemic therapy.

Biologically, recurrent cervical cancer remains strongly linked to human papillomavirus (HPV) infection, especially high-risk HPV types such as HPV16. Recent research continues to emphasize the tumor microenvironment, immune evasion, PI3K/Akt signaling, TGF-β-related pathways, and resistance to cisplatin and radiotherapy. checkpoint inhibitor, anti-PD-L1 strategies, and combination approaches with agents such as bevacizumab, pembrolizumab, cemiplimab, and alpelisib are being explored to improve outcomes in recurrent or metastatic disease.

Focus of Latest Publications

Recent publications portray recurrent cervical cancer as a major focus of translational oncology, particularly in the context of immunotherapy, biomarker development, and resistance mechanisms. A clinical study reported that clinical and nutritional-inflammatory biomarkers were used to build a nomogram predicting survival in recurrent or metastatic cervical cancer treated with immune checkpoint inhibitors, underscoring the need for personalized prognostic tools in this setting. Another real-world cohort from Norway examined oncologic outcomes and immune-checkpoint-blockade-induced toxicities in patients with cervical cancer, reflecting the growing use of programmed cell death 1 blockade in recurrent or metastatic disease and its associated adverse-event profile.

Several studies emphasized that immune checkpoint inhibitors have changed the treatment landscape, but benefit remains limited or short-lived for many patients. One report described the introduction of immune checkpoint inhibitors as significantly prolonging survival in metastatic or recurrent cervical cancer, while another highlighted that PD-1 blockade is currently the only approved immunotherapy for this disease and that efficacy remains constrained by immune evasion. Related work investigated CD155 as a link between tumor immunotype and epithelial-directed precision therapy beyond checkpoint inhibition, and IGSF3 binding to TNFR2 on regulatory T cells to facilitate immunosuppression, both pointing to the complexity of the immune microenvironment in recurrent disease. A separate study developed an immune infiltration-based gene signature to predict prognosis and immunotherapy response to an anti-PD-L1/TGF-β bifunctional fusion protein, suggesting that combined checkpoint and TGF-β-directed approaches may be relevant in recurrent cervical cancer.

Targeted therapy research has also expanded. One study found that PIK3CA-mutant cervical cancer was selectively suppressed by PIK3CA inhibition with alpelisib and inavolisib, and that this strategy cooperated with HPV-directed T cell therapy. This supports the idea that molecularly defined recurrent tumors may be amenable to precision treatment. Another study reported that simvastatin restored cisplatin sensitivity in cisplatin-resistant cervical cancer cells by suppressing Caveolin-1-mediated PI3K/AKT signaling, highlighting a possible route to overcome chemotherapy resistance. Additional preclinical work examined compounds such as luteolin, apigeninidin derivatives, Paris polyphylla saponin II, and other candidate agents that inhibited cervical cancer cell growth through pathways including CA2 suppression, PARP1 targeting, and autophagy-associated ferroptosis.

Radiation response and resistance were also prominent themes. A planning study evaluated online adaptive SBRT boost with a 1.5-T MR-Linac for cervical cancer patients unsuitable for brachytherapy, indicating ongoing efforts to optimize local control in difficult recurrent or advanced cases. Another study focused on radiotherapy resistance mediated by cancer-associated fibroblast-derived exosomes delivering BMP4, linking redox regulation, Nrf2 activation, and cuproptosis inhibition. An expression-of-concern article addressed promoter methylation of death-associated protein kinase and its role in irradiation response, reflecting continued interest in epigenetic determinants of radiosensitivity. More broadly, radiotherapy dose prediction frameworks and adaptive planning tools were also applied to cervical cancer treatment planning.

Metastatic behavior and tumor biology were investigated through multi-omics and imaging approaches. One study reported that lymph node metastasis is the primary mode of cervical cancer metastasis and is associated with poorer prognosis, while another used multiparametric MRI-based radiomics and deep learning to predict lymph node metastasis in early-stage disease. Multi-omics analysis also identified alterations in the tumor microbiome and metabolome associated with lymph node metastasis. Integrated multi-omics and intratumoral heterogeneity-corrected prognostic signatures were developed to improve outcome prediction, reflecting the challenge of heterogeneity in recurrent and advanced cervical cancer.

Prevention and early detection remain central to reducing future recurrence burden. Multiple studies addressed HPV vaccination awareness, uptake, refusal, and cost-effectiveness in China, Morocco, Ethiopia, Jordan, Singapore, and other settings. These studies reinforced that HPV vaccination is an effective strategy to avert cervical cancer, while screening coverage and vaccine uptake remain suboptimal in many low-resource settings. A multicenter study in India described implementation research to improve screening, early diagnosis, and treatment initiation for cervical cancer, and another study examined discrepancies between colposcopic-directed biopsy and conization to reduce missed diagnoses and unnecessary procedures. Together, these findings situate recurrent cervical cancer within a broader prevention-to-treatment continuum shaped by HPV vaccination, screening, and timely intervention.

Key Publications

• NEWJun Uncovering metabolic reprogramming in ovarian and cervical cancers with multi-omics. (iScience, 2026, PMID 42109858): "Ovarian cancer (OC) and cervical cancer (CC) are major causes of gynecological malignancy mortality, but their spatially resolved metabolic features and shared progression-driving metabolic reprogramming remain unexplored."
• Jun Dosimetric comparison of high dose rate interstitial brachytherapy and stereotactic body radiotherapy as alternative treatment methods for advanced-stage cervical cancer. (Biomedical physics & engineering express, 2026, PMID 42259310): "High-dose-rate interstitial brachytherapy (HDR-IBT) is an essential component of curative treatment for locally advanced cervical cancer, but it is invasive and resource-intensive."
• Jun Gaps and barriers preventing sustained delivery of HPV vaccination in Kano, Kaduna, and Lagos states: An exploratory qualitative study. (PloS one, 2026, PMID 42313828): "To lessen the burden of cervical cancer, Nigeria introduced the HPV vaccine to its national immunization program, but the program has faced operational and contextual problems during its early rollout."
• Jun Oncolytic human adenovirus 5 (H101) modulates cell cycle progression in HPV16-positive tumors. (Biochemical and biophysical research communications, 2026, PMID 42000628): "Cervical cancer remains a major threat to women's health."
• Jun Understanding factors influencing HPV vaccine uptake among caregivers in Kwara State, Nigeria: A qualitative study. (PloS one, 2026, PMID 42302043): "Human papillomavirus (HPV) vaccine prevents over 90% of cervical cancers."
• Jun Preventive and therapeutic efficacy of mRNA/LNP vaccines encoding HPV16 E6 and E7 in an early-intervention HPV tumor mouse models. (Human vaccines & immunotherapeutics, 2026, PMID 42301768): "Persistent infection with high-risk human papillomavirus (HPV) drives the development of cervical and other anogenital cancers, with limited therapeutic options for early-stage disease and precancerous lesions."
• Jun Human papillomavirus vaccination: knowledge, acceptance, and barriers among medical students. An Egyptian multicenter cross sectional study. (Scientific reports, 2026, PMID 42297846): "Human papillomavirus (HPV) infection is a major public health concern and a leading cause of cervical cancer worldwide."
• Jun From global to local: Developing a context-specific BeSD-HPV tool through cultural and linguistic adaptation in Pakistan. (PloS one, 2026, PMID 42296125): "A key challenge in preventing cervical cancer is the low uptake of the Human Papillomavirus (HPV) vaccine in low and middle-income countries (LMICs)."
• Jun Early effects of HPV vaccination on high-grade cervical intraepithelial neoplasia in Brazil: Evidence from outpatient data. (Human vaccines & immunotherapeutics, 2026, PMID 42295873): "Cervical cancer remains a leading cause of disease burden among women, despite being largely preventable."
• Jun Paris polyphylla saponin Ⅱ induces autophagy-associated ferroptosis by regulating the BECLIN1/SLC7A11 axis in cervical cancer. (European journal of pharmacology, 2026, PMID 42162690): "Cervical cancer remains a lethal gynecologic malignancy requiring novel therapies."